BEIGENE LTD-ADR (BGNE) Stock News

USA - NASDAQ:BGNE - US07725L1026 - ADR

184.71 USD

+0.9 (+0.49%)

Last: 12/31/2024, 8:10:09 PM

184.71 USD

0 (0%)

After Hours: 12/31/2024, 8:10:09 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BGNE Latest News, Press Relases and Analysis

All

Press Releases

5 months ago - By: Yahoo Finance - Mentions: SMMT WRD PONY BMRN ...

Why Summit Therapeutics Rocketed Double-Digits Today

5 months ago - By: The Motley Fool - Mentions: SMMT

Why Summit Therapeutics Rocketed Double-Digits Today

6 months ago - By: BeiGene, Ltd.

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

10 months ago - By: Benzinga

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts

10 months ago - By: Benzinga

Why Is BeiGene Stock Trading Higher On Wednesday?

9 months ago - By: BeiGene, Ltd.

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

9 months ago - By: BeiGene, Ltd.

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

10 months ago - By: BeiGene, Ltd.

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

10 months ago - By: BeiGene, Ltd.

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

10 months ago - By: BeiGene, Ltd.

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

10 months ago - By: BeiGene, Ltd.

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

10 months ago - By: BeiGene, Ltd.

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

10 months ago - By: BeiGene, Ltd.

BeiGene to Present at Upcoming Investor Conferences

11 months ago - By: Labcorp Holdings Inc - Mentions: LH

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

11 months ago - By: BeiGene, Ltd.

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

a year ago - By: Bloomberg

China-Origin Drugmaker BeiGene to Rename Itself Amid Global Push

a year ago - By: BeiGene, Ltd.

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

a year ago - By: BeiGene, Ltd.

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

a year ago - By: BeiGene, Ltd.

BeiGene to Present at the Jefferies London Healthcare Conference

a year ago - By: BeiGene, Ltd.

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

a year ago - By: BeiGene, Ltd.

BeiGene Mourns Death of Beloved Board Member Donald Glazer

a year ago - By: Bloomberg

China Detains Ex-AstraZeneca Executive in Sign of Widening Probe

a year ago - By: BeiGene, Ltd.

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

a year ago - By: BeiGene, Ltd.

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

a year ago - By: BeiGene, Ltd.

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

a year ago - By: BeiGene, Ltd.

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

a year ago - By: BeiGene, Ltd.

BeiGene Announces Updates to Commercial Leadership Team